DUO RUI PHARMA released its performance for the first three quarters, with a net loss attributable to the parent company of 79.7277 million yuan
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, DUO RUI PHARMA released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 137 million yuan, a year-on-year decrease of 43.07%. The net loss attributable to shareholders of the listed company was 79.7277 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 84.9485 million yuan. The basic loss per share was 1.0064 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments